Home|Prescribing Information|Contact Us|Site Map
Treating CPP

The first step in treating CPP is performing a series of medical tests to determine whether your child has CPP and, if so, what kind. Some children have “secondary” CPP—that is, something other than the pituitary gland is causing the signs of puberty. For “secondary” CPP, the underlying problem can be diagnosed and treated, which generally causes the progression of early puberty associated with CPP to stop. If your child has “true” CPP—meaning the early puberty isn’t caused by something else—your doctor will recommend appropriate treatment.

The diagnostic tests begin with a complete medical history and a physical examination. Your child may be given some or all of the following tests:

  • Hand/wrist x-rays to reveal whether the bones have matured early
  • Blood tests to check the levels of different hormones
  • GnRH stimulation test to determine if the pituitary hormones are at pubertal levels
  • Pelvic and adrenal ultrasound to assess the size of ovaries, testicles, adrenals
  • Magnetic resonance imaging (MRI) or computer-assisted tomography (CAT) scans of the head to determine whether the hypothalamus and pituitary gland are normal
Register with SUPPRELIN LA

Indication

SUPPRELIN® LA (histrelin acetate) implant is used for the treatment of children with central precocious puberty (CPP).

Important Safety Information

SUPPRELIN LA should not be used by women who are or may become pregnant, and in patients who are allergic to gonadotropin releasing hormone (GnRH) or GnRH agonist analogs. Safety and effectiveness in children under 2 years of age has not been determined.

SUPPRELIN LA, like other GnRH agonists, may cause a temporary increase in the blood levels of specific hormones associated with the onset of puberty (estrogen in girls and testosterone in both sexes) during the first week of treatment. This increase may temporarily worsen puberty symptoms during the first week, additionally, you may see new symptoms appear during this period. Within the 4 weeks of treatment with SUPPRELIN LA, hormonal suppression generally occurs and the physical signs of puberty should decrease.

Your doctor should monitor the levels of specific hormones associated with puberty progression, 1 month after starting SUPPRELIN LA and then every 6 months thereafter. Every 6-12 months, height and bone age should be also monitored by your doctor.

During the clinical trial testing of SUPPRELIN LA, the most common side effects involved the implant site and included temporary bruising, pain, soreness, redness of the skin and swelling.

Please talk with your doctor for more information or if you have any questions.

Endo Pharmaceuticals
Rx Only
© 2010 Endo Pharmaceuticals. All rights reserved.
SUPPRELIN® LA is a registered trademark of Endo Pharmaceuticals.
SP-1007/June 2009

Privacy/Legal
Intended for U.S. Residents Only